Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Change in Accured Expenses (2022 - 2026)

TriSalus Life Sciences has reported Change in Accured Expenses over the past 5 years, most recently at $160000.0 for Q1 2026.

  • For Q1 2026, Change in Accured Expenses fell 90.15% year-over-year to $160000.0; the TTM value through Mar 2026 reached $556000.0, up 122.65%, while the annual FY2025 figure was $2.0 million, 146.08% up from the prior year.
  • Change in Accured Expenses for Q1 2026 was $160000.0 at TriSalus Life Sciences, down from $692000.0 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $5.4 million in Q4 2023 and troughed at -$4.6 million in Q3 2023.
  • A 5-year average of $345882.4 and a median of $214728.0 in 2022 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: crashed 1486.36% in 2024 and later skyrocketed 632.46% in 2025.
  • Year by year, Change in Accured Expenses stood at $4.1 million in 2022, then skyrocketed by 30.69% to $5.4 million in 2023, then plummeted by 94.43% to $301000.0 in 2024, then surged by 129.9% to $692000.0 in 2025, then crashed by 76.88% to $160000.0 in 2026.
  • Business Quant data shows Change in Accured Expenses for TLSI at $160000.0 in Q1 2026, $692000.0 in Q4 2025, and $1.5 million in Q3 2025.